Assertio Shares Jump as Garda Raises All-Cash Buyout Offer to $21.80 Per Share ($153M Deal)
Garda raised bid to $21.80/share cash to buy Assertio, boosting stock ~17%. Deal gives shareholders higher, certain payout.
/ 1656 items
#XY↓
Eli Lilly Dismisses Foundayo Liver Report as 'Statistical Background Noise' — RBC Maintains Outperform
Eli Lilly states that a post-launch report of hepatic failure for Foundayo (orforglipron) is not plausibly linked to the drug. RBC Capital describes it as “statistical background noise.”
FDA Gives Green Light: Clene’s New ALS Drug Moves Closer to Faster Approval
FDA may fast-track Clene’s ALS drug CNM-Au8 after strong results, offering hope for longer life and slower disease progression.
“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
FDA Approves First-Ever PROTAC Drug Veppanu for Advanced Breast Cancer with ESR1 Mutation
FDA approved Pfizer/Arvinas Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases.
Summit Therapeutics Drops 21%: The “Continue” News That Spooked Investors
Summit stock fell after its cancer drug update was just “keep going,” not the big win investors hoped for.